Genome Sequencing Company Plans to Develop Liquid Biopsy for Cancer Detection

Grail’s test will use Illumina’s DNA sequencing technology to scan for bits of cancer genes originating in tumors and circulating in the bloodstream. The hope is to detect many types of newly forming tumors, which could be treated at an earlier stage to increase the chances of survival.

Illumina Chief Executive, Jay Flatley, who will serve as Chairman of Grail, said, “We hope today is a turning point in the war on cancer. By enabling the early detection of cancer in asymptomatic individuals through a simple blood screen, we aim to massively decrease cancer mortality by detecting the disease at a curable stage.”

Source: Medindia

Source link
#Genome #Sequencing #Company #Plans #Develop #Liquid #Biopsy #Cancer #Detection

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *